Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.
作者信息
Choby Jacob E, Ozturk Tugba, Satola Sarah W, Jacob Jesse T, Weiss David S
机构信息
Emory Antibiotic Resistance Center and Emory Vaccine Center, Atlanta, GA 30329, USA.
Emory Antibiotic Resistance Center and Emory Vaccine Center, Atlanta, GA 30329, USA; Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA; Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta, GA, USA.
出版信息
Lancet Infect Dis. 2021 May;21(5):597-598. doi: 10.1016/S1473-3099(21)00194-8.
Abstract
摘要
相似文献
1
Widespread cefiderocol heteroresistance in carbapenem-resistant Gram-negative pathogens.
Lancet Infect Dis. 2021 May;21(5):597-598. doi: 10.1016/S1473-3099(21)00194-8.
2
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
3
Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
J Antimicrob Chemother. 2017 Jun 1;72(6):1704-1708. doi: 10.1093/jac/dkx049.
4
Activities of Cefiderocol with Simulated Human Plasma Concentrations against Carbapenem-Resistant Gram-Negative Bacilli in an Chemostat Model.
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.01128-20.
5
Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study).
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.00093-17. Print 2017 Sep.
6
In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units.
Diagn Microbiol Infect Dis. 2020 May;97(1):115012. doi: 10.1016/j.diagmicrobio.2020.115012. Epub 2020 Feb 4.
7
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Lancet Infect Dis. 2018 Dec;18(12):1319-1328. doi: 10.1016/S1473-3099(18)30554-1. Epub 2018 Oct 25.
8
Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014.
Antimicrob Resist Infect Control. 2018 Nov 19;7:137. doi: 10.1186/s13756-018-0430-1. eCollection 2018.
9
Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship.
Eur J Med Chem. 2018 Jul 15;155:847-868. doi: 10.1016/j.ejmech.2018.06.014. Epub 2018 Jun 8.
10
Cefiderocol: A Siderophore Cephalosporin.
Ann Pharmacother. 2020 Dec;54(12):1215-1231. doi: 10.1177/1060028020929988. Epub 2020 Jun 10.
引用本文的文献
1
Combinatorial action of regulatory systems generates colistin heteroresistance.
bioRxiv. 2025 Aug 12:2025.08.11.668767. doi: 10.1101/2025.08.11.668767.
2
treatment strategies: a review of therapeutic challenges and considerations.
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0106324. doi: 10.1128/aac.01063-24. Epub 2025 Jul 9.
3
Droplet microfluidics-based detection of rare antibiotic-resistant subpopulations in from bloodstream infections.
Sci Adv. 2025 Jul 4;11(27):eadv4558. doi: 10.1126/sciadv.adv4558.
4
Copy number flexibility facilitates heteroresistance to increasing antibiotic pressure and threatens the beta-lactam pipeline.
Nat Commun. 2025 Jul 1;16(1):5721. doi: 10.1038/s41467-025-60828-9.
5
Emergence of NDM-1- and OXA-23-Co-Producing ST1 Isolates from a Burn Unit in Spain.
Microorganisms. 2025 May 16;13(5):1149. doi: 10.3390/microorganisms13051149.
6
Carbapenem-resistant Gram-negative bacteria exhibiting clinically undetected cefiderocol heteroresistance leads to treatment failure in a murine model of infection.
Front Microbiol. 2025 May 9;16:1496514. doi: 10.3389/fmicb.2025.1496514. eCollection 2025.
7
Overview of heteroresistance to multiple antibiotics in clinical isolates and combination therapeutic strategies.
JAC Antimicrob Resist. 2025 May 13;7(3):dlaf071. doi: 10.1093/jacamr/dlaf071. eCollection 2025 Jun.
8
The Multifaceted Landscape of Healthcare-Associated Infections Caused by Carbapenem-Resistant .
Microorganisms. 2025 Apr 5;13(4):829. doi: 10.3390/microorganisms13040829.
9
A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.
Antibiotics (Basel). 2025 Feb 21;14(3):221. doi: 10.3390/antibiotics14030221.
10
Prevalence, misclassification, and clinical consequences of the heteroresistant phenotype in Escherichia coli bloodstream infections in patients in Uppsala, Sweden: a retrospective cohort study.
Lancet Microbe. 2025 Apr;6(4):101010. doi: 10.1016/j.lanmic.2024.101010. Epub 2025 Jan 16.
本文引用的文献
1
Colistin Heteroresistance Is Largely Undetected among Carbapenem-Resistant in the United States.
mBio. 2021 Jan 26;12(1):e02881-20. doi: 10.1128/mBio.02881-20.
2
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12.
3
Carbapenem-Resistant Exhibiting Clinically Undetected Colistin Heteroresistance Leads to Treatment Failure in a Murine Model of Infection.
mBio. 2018 Mar 6;9(2):e02448-17. doi: 10.1128/mBio.02448-17.
4
Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01968-17. Print 2018 Feb.
5
Antibiotic failure mediated by a resistant subpopulation in Enterobacter cloacae.
Nat Microbiol. 2016 May 9;1(6):16053. doi: 10.1038/nmicrobiol.2016.53.
Zotero 插件